보고서 요약(국문)

개요
전 세계 저혈량성 쇼크 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
저혈량성 쇼크는 심각한 혈액 또는 체액 손실로 인해 심장이 신체에 충분한 혈액을 공급하지 못하는 응급 상태입니다. 이러한 유형의 쇼크는 여러 장기의 기능 부전을 초래할 수 있습니다. 심각한 출혈, 탈수, 화상, 구토, 설사 또는 과도한 발한과 같은 다양한 요인이 이 증후군을 유발할 수 있습니다. 저혈량성 쇼크는 신속한 의료 처치가 필요하며, 치료하지 않으면 치명적일 수 있습니다.
정맥 주사(IV) 수액은 혈액량을 빠르게 증가시키고 혈압을 낮추기 위해 저혈량성 쇼크 치료에 자주 사용됩니다. 심각한 출혈이 있는 경우에는 수혈이 필요할 수 있습니다. 또한 탈수 치료 또는 지혈과 같은 쇼크의 근본 원인을 파악하고 치료하는 것이 중요합니다. 시장 동향: 성장 동력 및 제약 요인
저혈량성 쇼크 치료 연구 개발 증가
전 세계 저혈량성 쇼크 치료 시장은 이 분야의 연구 개발 증가에 힘입어 성장할 것으로 예상됩니다. 예를 들어, Pharmazz, Inc.는 2021년 9월 미국 FDA가 저혈량성 쇼크 치료를 위해 개발한 약물 후보 물질인 센타퀸(centhaquine)의 3상 임상 연구를 승인했다고 발표했습니다.
총 430명의 환자를 두 군으로 무작위 배정하여 진행하는 이 3상 임상 연구의 주요 평가 변수는 28일 사망률입니다. 이 연구는 다기관, 이중맹검, 위약 대조 시험으로 진행될 예정입니다. Pharmazz의 환자 모집은 2021년 말 또는 2022년 초에 시작될 것으로 예상됩니다.
충돌, 낙상 또는 기타 유형의 외상으로 인한 심각한 부상은 급격하고 심각한 출혈을 유발하여 저혈량성 쇼크를 일으킬 수 있습니다. 심각한 탈수는 체액량을 감소시켜 혈액량까지 줄입니다. 구토, 설사, 과도한 발한, 특히 더운 날씨나 격렬한 운동 후 수분 섭취 부족은 저혈량성 쇼크를 유발할 수 있으며, 이러한 요인들이 시장 성장을 촉진합니다.
시장 동향: 제약 요인
저혈량성 쇼크는 응급 상황이므로 신속한 치료를 위해서는 병원 환경이 필수적입니다. 의료 시스템에는 저혈량성 쇼크의 관리 또는 치료에 영향을 미치는 제약이나 장애 요인이 있을 수 있습니다. 예를 들어, 의료 시설에 대한 접근성이 부족하거나 의료 지원을 받는 데 지연이 발생하는 경우 저혈량성 쇼크를 효과적으로 치료하기 어려울 수 있습니다.
또한, 일부 지역, 특히 저개발 국가에서는 제대로 갖춰진 의료 시설, 자격을 갖춘 의료진, 충분한 의료 물품의 부족으로 인해 저혈량성 쇼크를 시기적절하고 효과적으로 치료하기 어려울 수 있습니다. 특히 건강 보험이 없거나 공공 의료 지원이 부족한 지역에서는 높은 의료비로 인해 신속하고 적절한 의료 서비스를 받기가 어려울 수 있습니다.

보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 저혈량성 쇼크 시장은 유형, 치료법, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.
유형 세그먼트 중 출혈성 쇼크 세그먼트는 저혈량성 쇼크 시장의 약 49.7%를 차지했습니다.
심각한 출혈이 발생하면 잠재적으로 치명적인 질환인 출혈성 쇼크가 발생합니다. 이 상태는 응급 상황이므로 신속한 치료가 필요합니다. 뇌, 심장, 신장, 간과 같은 주요 장기는 혈액을 통해 산소와 영양분을 공급받습니다.
출혈성 쇼크에서 혈액 공급이 감소하면 이러한 장기에 산소와 영양분이 공급되지 않아 장기 기능 장애 또는 부전이 발생합니다. 혈액량 부족으로 심장의 혈액 펌프 기능이 저하됩니다. 이로 인해 심장 박동 불규칙, 심박출량 감소, 궁극적으로 심정지가 발생할 수 있습니다. 출혈성 쇼크는 특히 신속하고 효과적으로 치료하지 않으면 사망률이 매우 높습니다.

생존 가능성을 높이기 위해서는 수액 보충, 수혈, 출혈의 외과적 지혈과 같은 신속한 개입이 필수적입니다. 출혈성 쇼크는 특히 외상과 관련된 경우 예방 가능한 경우가 많습니다. 신속한 의료 개입, 더 나은 외상 치료, 그리고 대중 교육을 통해 출혈성 쇼크 관련 사망을 예방할 수 있습니다.
지역 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
예측 기간 동안 매출 점유율 측면에서도 북미가 주도적인 역할을 할 것으로 예상됩니다. 의료비 지출 증가, 의료 시설 개선, 질병 특이적 치료에 대한 수요 증가, 연구 개발에 대한 투자 확대, 그리고 저혈량성 쇼크 치료를 위한 FDA 승인 의약품 수 증가는 모두 의료 부문의 급속한 기술 발전에 기여하는 요인입니다.
예를 들어, 미국 의사협회(AMA)는 2021년 미국의 의료비 지출이 2.7% 증가한 4조 3천억 달러, 즉 1인당 12,914달러에 달했다고 추산합니다. 이 성장률은 2020년 성장률 전망치(10.3%)보다 상당히 낮습니다. 이러한 지출의 상당한 둔화는 팬데믹 관련 비용에 대한 정부 지출 감소와, 2020년 치료 지연 및 억눌린 수요로 인해 회복되었던 의료 용품 및 서비스 사용 증가를 상쇄한 데 기인합니다. 따라서 의료비 지출 증가는 이 지역의 경제 발전을 가속화할 것입니다.
신흥국의 의료비 증가와 저혈량성 쇼크 치료 수요 증가로 인해 아시아 태평양 지역은 예측 기간 동안 높은 매출 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 이 지역 시장은 고령화, 의료 인식 향상, 그리고 중국과 인도와 같은 개발도상국에 더욱 집중하는 주요 제조업체 등의 요인에 의해 주도되고 있습니다.
COVID-19 영향 분석
혈전 및 기타 비정상적인 응고 과정은 모두 COVID-19와 관련이 있습니다. 심부정맥혈전증(DVT)과 폐색전증(PE)은 이러한 혈전이 중요한 혈관을 막을 때 발생할 수 있는 두 가지 질환입니다. 이러한 응고 장애는 심각하고 광범위하게 나타날 경우 상당한 출혈과 저혈량성 쇼크를 유발할 수 있습니다. 패혈증은 감염에 대한 면역 반응의 불균형으로 발생하는 치명적인 질환으로, 중증 코로나19 환자에게서 발생할 수 있습니다.
패혈증은 광범위한 염증과 혈관 투과성 증가를 유발하여 체액 손실 및 저혈량성 쇼크로 이어질 수 있습니다. 코로나19 팬데믹이 절정에 달했을 당시 일부 지역의 의료 시스템이 과부하 상태에 빠지면서 외상 환자와 같은 코로나19 이외의 상황에 대한 의료 처치가 지연되었습니다. 심각한 상처나 내부 출혈에 대한 치료가 지연되면 저혈량증이 발생할 수 있습니다.

시장 세분화
유형별
• 출혈성
• 비출혈성
치료법별
• 약물
o 에피네프린
o 노르에피네프린
o 도파민
o 도부타민
• 요법
투여 경로별
• 경구
• 정맥 주사
최종 사용자별
• 병원
• 클리닉
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer Inc, Viatris Inc, AstraZeneca Pharma Ltd, Wellona Pharma Ltd, Baxter Inc, Anant Pharmaceuticals Pvt. Ltd 등이 있습니다. Ltd, REWINE PHARMACEUTICAL, Hikma Pharmaceuticals, PLC, LEXICARE PHARMA PVT. LTD, Taj Pharma Group 등을 포함한 여러 기업.

보고서 구매 이유:

• 유형, 치료법, 투여 경로, 최종 사용자 및 지역별 글로벌 저혈량성 쇼크 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 저혈량성 쇼크 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트 제공.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공.

• 주요 기업의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑 제공.

글로벌 저혈량성 쇼크 시장 보고서는 약 69개의 표, 58개의 그림, 187페이지 분량입니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Hypovolemic Shock Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Hypovolemic shock is an emergency condition in which severe blood or other fluid loss makes the heart unable to pump enough blood to the body. This type of shock can cause many organs to stop working. Numerous factors, such as severe bleeding, dehydration, burns, vomiting, diarrhoea, or extreme perspiration, might contribute to this syndrome. Hypovolemic shock necessitates quick medical attention and, if untreated, can be lethal.
Intravenous (IV) fluids are frequently used as a treatment for hypovolemic shock in order to quickly increase blood volume and lower blood pressure. Blood transfusions may be required in circumstances of severe bleeding. It's also essential to determine and treat the shock's underlying causes, such as treating dehydration or halting bleeding.
Market Dynamics: Drivers and Restraints
The rising research and development on hypovolemic shock treatment
The expansion of the worldwide hypovolemic shock treatment market is anticipated to be driven by an increase in research and development in this field. For instance, Pharmazz, Inc. reported in September 2021 that the US FDA had authorised the Phase III clinical research of the drug candidate centhaquine it had conducted for the management of hypovolemic shock.
The primary endpoint of the Phase III clinical investigation, which will involve 430 patients randomly divided equally into both arms, will be 28-day mortality. It will be a multi-centric, double-blind, placebo-controlled trial. Enrollment in Pharmazz should start towards the end of 2021 or the start of 2022.
Serious wounds from collisions, falls, or other types of trauma can also result in rapid and significant blood loss, which can produce hypovolemic shock. Severe dehydration decreases the body's fluid volume, which also lowers blood volume. Vomiting, diarrhoea, excessive perspiration, or a lack of fluid intake, particularly in hot weather or after vigorous exertion, can cause the disease and thus above factors helps to boost the market growth.
Market Dynamics: Restraint
A hospital setting is required for prompt treatment of hypovolemic shock, which is a medical emergency. The healthcare system may have restraints or impediments that affect the management or treatment of hypovolemic shock. For instance, it may be difficult to treat hypovolemic shock effectively if there is insufficient access to medical facilities or a delay in receiving assistance.
Additionally, in some areas, particularly in poor nations, a lack of well outfitted medical facilities, qualified medical staff, or sufficient medical supplies may make it difficult to treat hypovolemic shock in a timely and effective manner. Receiving prompt and proper medical care can be hampered by high healthcare expenses, particularly for those without health insurance or in areas where healthcare is not publicly financed.
For more details of the report, Request for sample
Segment Analysis
The global hypovolemic shock market is segmented based on type, treatment, route of administration, end-user and region.
The hemorrhagic shock segment from the type segment accounted for approximately 49.7% of hypovolemic market
When a person experiences significant bleeding, hemorrhagic shock, a potentially fatal illness, develops. This condition necessitates quick attention and treatment because it is a medical emergency. Vital organs like the brain, heart, kidneys, and liver receive oxygen and nourishment through the blood.
The decreased blood supply in hemorrhagic shock deprives these organs of oxygen and nutrients, resulting in organ dysfunction or failure.The heart's ability to pump blood efficiently is impacted by insufficient blood volume. Heart rhythm irregularities, a reduction in cardiac output, and ultimately cardiac arrest can result from this. A high fatality rate is associated with hemorrhagic shock, particularly if it is not promptly and efficiently treated.
To increase the likelihood of life, quick intervention, such as fluid replacement, blood transfusions, and surgical control of bleeding, is necessary. Hemorrhagic shock is often avoidable, especially in trauma-related instances. Hemorrhagic shock-related mortality can be avoided with the help of quick medical intervention, better trauma treatment, and public education.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
In terms of revenue share during the forecast period, North America is anticipated to dominate. Increasing healthcare spending, improving healthcare facilities, increased demand for disease-specific treatments, increased emphasis on research and development, and an increase in the number of FDA-approved medications for treating hypovolemic shock are all contributing factors to the healthcare sector's rapid technological evolution.
For instance, the American Medical Association (AMA) estimates that health spending in the U.S. increased by 2.7% in 2021 to $4.3 trillion, or $12,914 per person. This growth rate is considerably less than the 2020 growth forecast (10.3%%). This significant slowdown in spending can be linked to a drop in government spending on pandemic-related expenses countering an increase in the use of medical supplies and services that recovered from 2020 owing to delayed care and pent-up demand. Thus, the increase in healthcare spending will accelerate the region's economic development.
Due to increased healthcare costs in emerging nations and a growth in demand for hypovolemic shock treatment, Asia Pacific is anticipated to grow at a high revenue CAGR over the projected period. The region's market is driven by factors such as an ageing population, growing healthcare awareness, and prominent manufacturers focusing more on developing nations like China and India.
COVID-19 Impact Analysis
Blood clots and other aberrant coagulation processes have both been linked to COVID-19. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are two disorders that can occur when these blood clots block important blood veins. These coagulation abnormalities have the potential to cause considerable bleeding and hypovolemic shock if they are severe and widespread. Sepsis, a disorder that can be fatal that is brought on by an unbalanced immunological response to infection, can result from severe COVID-19 cases.
Sepsis can cause extensive inflammation and leaky blood vessels, which can lead to fluid loss and perhaps hypovolemic shock. Medical attention for situations other than COVID-19, such as trauma cases, was delayed during the pandemic's peak because some regions' healthcare systems were overburdened. Hypovolemia may develop from delaying the treatment of severe wounds or internal bleeding.
Market Segmentation
By Type
• Hemorrhagic
• Non-hemorrhagic
By Treatment
• Medication
o Epinephrine
o Norepinephrine
o Dopamine
o Dobutamine
• Therapy
By Route of Administration
• Oral
• Intravenous
By End-User
• Hospitals
• Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc, Viatris Inc, AstraZeneca Pharma Ltd, Wellona Pharma Ltd, Baxter Inc, Anant Pharmaceuticals Pvt. Ltd, REWINE PHARMACEUTICAL, Hikma Pharmaceuticals, PLC, LEXICARE PHARMA PVT. LTD, Taj Pharma Group and among others.
Why Purchase the Report?
• To visualize the global hypovolemic shock market segmentation based on type, treatment, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hypovolemic shock market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hypovolemic shock market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by End-User
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising research and development on hypovolemic shock treatment
4.1.1.2. Increasing product approvals
4.2. Restraints
4.2.1.1. Limited access to healthcare facilities
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Hemorrhagic *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-hemorrhagic
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Medication *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Epinephrine
8.2.4. Norepinephrine
8.2.5. Dopamine
8.2.6. Dobutamine
8.3. Therapy
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Viatris Inc
13.3. AstraZeneca Pharma Ltd
13.4. Wellona Pharma Ltd
13.5. Baxter Inc
13.6. Anant Pharmaceuticals Pvt. Ltd
13.7. REWINE PHARMACEUTICAL
13.8. Hikma Pharmaceuticals PLC
13.9. LEXICARE PHARMA PVT. LTD
13.10. Taj Pharma Group
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc, 4.	Key Developments, Viatris Inc, AstraZeneca Pharma Ltd, Wellona Pharma Ltd, Baxter Inc, Anant Pharmaceuticals Pvt. Ltd, REWINE PHARMACEUTICAL, Hikma Pharmaceuticals PLC, LEXICARE PHARMA PVT. LTD, Taj Pharma Group

표 목록 (Tables)

List of Tables

Table 1 Global Hypovolemic Shock Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Hypovolemic Shock Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Hypovolemic Shock Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Hypovolemic Shock Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Hypovolemic Shock Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Hypovolemic Shock Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Hypovolemic Shock Market Value, By Type, 2021-2030 (US$ Million)

Table 8 Global Hypovolemic Shock Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Hypovolemic Shock Market Value, By Treatment, 2021-2030 (US$ Million)

Table 10 Global Hypovolemic Shock Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Hypovolemic Shock Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Hypovolemic Shock Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Hypovolemic Shock Market Value, By End-User, 2021-2030 (US$ Million)

Table 14 Global Hypovolemic Shock Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Hypovolemic Shock Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Hypovolemic Shock Market Value, By Type, 2021-2030 (US$ Million)

Table 17 North America Hypovolemic Shock Market Value, By Treatment, 2021-2030 (US$ Million)

Table 18 North America Hypovolemic Shock Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Hypovolemic Shock Market Value, By End-User, 2021-2030 (US$ Million)

Table 20 North America Hypovolemic Shock Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Hypovolemic Shock Market Value, By Type, 2021-2030 (US$ Million)

Table 22 South America Hypovolemic Shock Market Value, By Treatment, 2021-2030 (US$ Million)

Table 23 South America Hypovolemic Shock Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Hypovolemic Shock Market Value, By End-User, 2021-2030 (US$ Million)

Table 25 South America Hypovolemic Shock Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Hypovolemic Shock Market Value, By Type, 2021-2030 (US$ Million)

Table 27 Europe Hypovolemic Shock Market Value, By Treatment, 2021-2030 (US$ Million)

Table 28 Europe Hypovolemic Shock Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Hypovolemic Shock Market Value, By End-User, 2021-2030 (US$ Million)

Table 30 Europe Hypovolemic Shock Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Hypovolemic Shock Market Value, By Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Hypovolemic Shock Market Value, By Treatment, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Hypovolemic Shock Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Hypovolemic Shock Market Value, By End-User, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Hypovolemic Shock Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Hypovolemic Shock Market Value, By Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Hypovolemic Shock Market Value, By Treatment, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Hypovolemic Shock Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Hypovolemic Shock Market Value, By End-User, 2021-2030 (US$ Million)

Table 40 Pfizer Inc: Overview

Table 41 Pfizer Inc: Product Portfolio

Table 42 Pfizer Inc: Key Developments

Table 43 Viatris Inc: Overview

Table 44 Viatris Inc: Product Portfolio

Table 45 Viatris Inc: Key Developments

Table 46 AstraZeneca Pharma Ltd: Overview

Table 47 AstraZeneca Pharma Ltd: Product Portfolio

Table 48 AstraZeneca Pharma Ltd: Key Developments

Table 49 Wellona Pharma Ltd: Overview

Table 50 Wellona Pharma Ltd: Product Portfolio

Table 51 Wellona Pharma Ltd: Key Developments

Table 52 Baxter Inc: Overview

Table 53 Baxter Inc: Product Portfolio

Table 54 Baxter Inc: Key Developments

Table 55 Anant Pharmaceuticals Pvt. Ltd: Overview

Table 56 Anant Pharmaceuticals Pvt. Ltd: Product Portfolio

Table 57 Anant Pharmaceuticals Pvt. Ltd: Key Developments

Table 58 REWINE PHARMACEUTICAL: Overview

Table 59 REWINE PHARMACEUTICAL: Product Portfolio

Table 60 REWINE PHARMACEUTICAL: Key Developments

Table 61 Hikma Pharmaceuticals PLC: Overview

Table 62 Hikma Pharmaceuticals PLC: Product Portfolio

Table 63 Hikma Pharmaceuticals PLC: Key Developments

Table 64 LEXICARE PHARMA PVT. LTD: Overview

Table 65 LEXICARE PHARMA PVT. LTD: Product Portfolio

Table 66 LEXICARE PHARMA PVT. LTD: Key Developments

Table 67 Taj Pharma Group: Overview

Table 68 Taj Pharma Group: Product Portfolio

Table 69 Taj Pharma Group: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 2 Global Hypovolemic Shock Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Hypovolemic Shock Market Share, By Treatment, 2022 & 2030 (%)

Figure 4 Global Hypovolemic Shock Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Hypovolemic Shock Market Share, By End-User, 2022 & 2030 (%)

Figure 6 Global Hypovolemic Shock Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Hypovolemic Shock Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Hemorrhagic Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 9 Non-hemorrhagic Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 10 Global Hypovolemic Shock Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 11 Medication Treatment in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 12 Therapy Treatment in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 13 Global Hypovolemic Shock Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Oral Route of Administration in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 15 Intravenous Route of Administration in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 16 Global Hypovolemic Shock Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 17 Hospitals End-User in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 18 Clinics End-User in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 19 Others End-User in Global Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 20 Global Hypovolemic Shock Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 24 South America Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 26 North America Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 27 North America Hypovolemic Shock Market Share, By Type, 2022 & 2030 (%)

Figure 28 North America Hypovolemic Shock Market Share, By Treatment, 2022 & 2030 (%)

Figure 29 North America Hypovolemic Shock Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 30 North America Hypovolemic Shock Market Share, By End-User, 2022 & 2030 (%)

Figure 31 North America Hypovolemic Shock Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 33 South America Hypovolemic Shock Market Share, By Type, 2022 & 2030 (%)

Figure 34 South America Hypovolemic Shock Market Share, By Treatment, 2022 & 2030 (%)

Figure 35 South America Hypovolemic Shock Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 South America Hypovolemic Shock Market Share, By End-User, 2022 & 2030 (%)

Figure 37 South America Hypovolemic Shock Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 39 Europe Hypovolemic Shock Market Share, By Type, 2022 & 2030 (%)

Figure 40 Europe Hypovolemic Shock Market Share, By Treatment, 2022 & 2030 (%)

Figure 41 Europe Hypovolemic Shock Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 Europe Hypovolemic Shock Market Share, By End-User, 2022 & 2030 (%)

Figure 43 Europe Hypovolemic Shock Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 45 Asia-Pacific Hypovolemic Shock Market Share, By Type, 2022 & 2030 (%)

Figure 46 Asia-Pacific Hypovolemic Shock Market Share, By Treatment, 2022 & 2030 (%)

Figure 47 Asia-Pacific Hypovolemic Shock Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Asia-Pacific Hypovolemic Shock Market Share, By End-User, 2022 & 2030 (%)

Figure 49 Asia-Pacific Hypovolemic Shock Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Hypovolemic Shock Market Value, 2021-2030 (US$ Million)

Figure 51 Middle East & Africa Hypovolemic Shock Market Share, By Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Hypovolemic Shock Market Share, By Treatment, 2022 & 2030 (%)

Figure 53 Middle East & Africa Hypovolemic Shock Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 54 Middle East & Africa Hypovolemic Shock Market Share, By End-User, 2022 & 2030 (%)

Figure 55 Pfizer Inc: Financials

Figure 56 Viatris Inc: Financials

Figure 57 AstraZeneca Pharma Ltd: Financials

Figure 58 Wellona Pharma Ltd: Financials

Figure 59 Baxter Inc: Financials

Figure 60 Anant Pharmaceuticals Pvt. Ltd: Financials

Figure 61 REWINE PHARMACEUTICAL: Financials

Figure 62 Hikma Pharmaceuticals PLC: Financials

Figure 63 LEXICARE PHARMA PVT. LTD: Financials

Figure 64 Taj Pharma Group: Financials

글로벌 저혈량성 쇼크 시장 – 2023-2030

Global Hypovolemic Shock Market - 2023-2030